Lymphoma & CLL Therapeutics

Outpatient administration of liso-cel: Preliminary results from the OUTREACH study

Due to concerns regarding adverse events (AEs), chimeric antigen receptor (CAR) T-cell therapies are predominantly...

Real-world outcomes in Germany with standard-of-care axi-cel and tisa-cel for large B-cell lymphoma

Following promising results in clinical trials, the CD19-targeted chimeric antigen receptor (CAR)...

Duvelisib receives a positive opinion from the EMA CHMP for the treatment of R/R CLL and refractory FL

On March 25, 2021, it was announced that duvelisib received a positive opinion from the European...

A four-factor prognostic model predicts outcome in patients with CLL treated with ibrutinib

Ibrutinib is a Bruton’s tyrosine kinase inhibitor with clinical efficacy for patients with...

FDA biologics license application of ublituximab plus umbralisib for the treatment of CLL

On March 29, 2021, it was announced that a biologics license application (BLA) was submitted to the U.S. Food...

Phase II study of lenalidomide and R-CHOP in patients with diffuse large B-cell lymphoma

Diffuse large B-cell lymphoma (DLBCL) is recognized to be a molecularly heterogenous malignancy. Of the three...

Educational theme: 5hmC profiles of cfDNA predict R-CHOP treatment response in patients with DLBCL

This article is part of our educational series on the role of circulating tumor DNA (ctDNA) in the...

Phase II results: MATRix-RICE therapy and ASCT in DLBCL with secondary CNS involvement

Patients with diffuse large B-cell lymphoma (DLBCL) and dissemination within the central nervous system (CNS)...